These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 23169884)
1. Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit. Iwase T; Oveson BC; Hashida N; Lima e Silva R; Shen J; Krauss AH; Gale DC; Adamson P; Campochiaro PA Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):503-11. PubMed ID: 23169884 [TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Derevjanik NL; Vinores SA; Xiao WH; Mori K; Turon T; Hudish T; Dong S; Campochiaro PA Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2462-7. PubMed ID: 12091451 [TBL] [Abstract][Full Text] [Related]
3. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Miki K; Miki A; Matsuoka M; Muramatsu D; Hackett SF; Campochiaro PA Ophthalmology; 2009 Sep; 116(9):1748-54. PubMed ID: 19643496 [TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822 [TBL] [Abstract][Full Text] [Related]
5. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Alikacem N; Yoshizawa T; Nelson KD; Wilson CA Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677 [TBL] [Abstract][Full Text] [Related]
7. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. Takahashi K; Saishin Y; Saishin Y; Silva RL; Oshima Y; Oshima S; Melia M; Paszkiet B; Zerby D; Kadan MJ; Liau G; Kaleko M; Connelly S; Luo T; Campochiaro PA FASEB J; 2003 May; 17(8):896-8. PubMed ID: 12670875 [TBL] [Abstract][Full Text] [Related]
8. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Castro MR; Lutz D; Edelman JL Exp Eye Res; 2004 Aug; 79(2):275-85. PubMed ID: 15325574 [TBL] [Abstract][Full Text] [Related]
9. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Edelman JL; Lutz D; Castro MR Exp Eye Res; 2005 Feb; 80(2):249-58. PubMed ID: 15670803 [TBL] [Abstract][Full Text] [Related]
10. Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. Robbie SJ; Lundh von Leithner P; Ju M; Lange CA; King AG; Adamson P; Lee D; Sychterz C; Coffey P; Ng YS; Bainbridge JW; Shima DT Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1490-500. PubMed ID: 23385800 [TBL] [Abstract][Full Text] [Related]
11. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Ozaki H; Hayashi H; Vinores SA; Moromizato Y; Campochiaro PA; Oshima K Exp Eye Res; 1997 Apr; 64(4):505-17. PubMed ID: 9227268 [TBL] [Abstract][Full Text] [Related]
13. Aflibercept Action in a Rabbit Model of Chronic Retinal Neovascularization: Reversible Inhibition of Pathologic Leakage With Dose-Dependent Duration. Cao J; MacPherson TC; Iglesias BV; Liu Y; Tirko N; Yancopoulos GD; Wiegand SJ; Romano C Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1033-1044. PubMed ID: 29450547 [TBL] [Abstract][Full Text] [Related]
14. Characterization of azurocidin as a permeability factor in the retina: involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown. Skondra D; Noda K; Almulki L; Tayyari F; Frimmel S; Nakazawa T; Kim IK; Zandi S; Thomas KL; Miller JW; Gragoudas ES; Hafezi-Moghadam A Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):726-31. PubMed ID: 18235021 [TBL] [Abstract][Full Text] [Related]
15. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Amrite AC; Ayalasomayajula SP; Cheruvu NP; Kompella UB Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1149-60. PubMed ID: 16505053 [TBL] [Abstract][Full Text] [Related]
17. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. Miki A; Miki K; Ueno S; Wersinger DM; Berlinicke C; Shaw GC; Usui S; Wang Y; Zack DJ; Campochiaro PA J Cell Physiol; 2010 Jul; 224(1):262-72. PubMed ID: 20232317 [TBL] [Abstract][Full Text] [Related]
18. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies. Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133 [TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier. Kim SR; Suh W Arch Pharm Res; 2017 Feb; 40(2):197-203. PubMed ID: 27988882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]